Immunological and pharmacological monitoring in the clinical use of cyclosporin A.
Immunological reactivity to donor antigens and serum concentrations of cyclosporin A were monitored in six patients after renal transplantation. At concentrations of 0.1--1.0 microgram/ml cyclosporin A prevented both donor-specific immune reactivity and clinical rejection during the early post-transplant course. Measurement of cyclosporin A levels and immunological indices allowed individual adjustment of the dosage so as to give excellent early graft function with few adverse effects.
D003524:Cyclosporins; D006085:Graft Survival / Q000187:drug effects; D006801:Humans; D007166:Immunosuppressive Agents / Q000097:blood* / Q000276:immunology; D016030:Kidney Transplantation; D010456:Peptides, Cyclic / Q000097:blood* / Q000276:immunology; D013601:T-Lymphocytes / Q000187:drug effects; D014184:Transplantation, Homologous
D003524:Cyclosporins; D007166:Immunosuppressive Agents; D010456:Peptides, Cyclic